Global Immunotherapy Drugs 2016-2020

免疫治療薬の世界市場:モノクローナル抗体、免疫チェックポイント阻害薬、ワクチン、非特異的免疫療法

◆タイトル:Global Immunotherapy Drugs 2016-2020
◆商品コード:IRTNTR8772
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2016年3月29日
◆ページ数:159
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:世界
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥270,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥324,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、免疫治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、免疫治療薬の世界市場規模及び予測、種類別分析、用途別分析、市場シェア、地域別分析/市場規模、市場の成長要因、市場の課題、市場動向、競争状況などの情報をお届けいたします。

About Immunotherapy Drugs

Immunotherapy enhances the innate powers of the immune system. The properties of the immune system to fight abnormal cells give immunotherapy drugs the chance of successfully fighting diseases such as cancer, respiratory, infectious, and autoimmune disorders.

Technavio’s analysts forecast the global immunotherapy drugs market to grow at a CAGR of 11.52% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global immunotherapy drugs market for the period 2015-2020. To calculate the market size, the report considers revenue generated from the sales of immunotherapy drugs used to treat cancer, respiratory, infectious, autoimmune, and inflammatory diseases. It also considers the revenues to be generated from the sales of drugs, which are expected to be launched into the market, along with the decline in revenues from the patent expiries of marketed drugs during the forecast period.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Immunotherapy Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• AbbVie Inc.
• Amgen Inc.
• Bristol-Myers Squibb Company (BMS)
• F. Hoffmann-La Roche AG
• Johnson & Johnson Private Ltd.
• Merck & Co. Inc.

[Other prominent vendors]
• AB Science
• Ablynx
• Acorda Therapeutics
• ADC Therapeutics
• Aduro Biotech
• Advantagene
• Advaxis
• Agensys Inc.
• Agenus Inc.
• Alder Biopharmaceuticals
• AlphaVax
• Altor BioScience
• Antares Pharma
• Antigen Express
• Argos Therapeutics Inc.
• Astellas Pharma
• AstraZeneca
• AVAX Technologies
• Bavarian Nordic
• Baxter
• Bayer
• Biogen
• Biotech Pharmaceutical
• Biothera
• Boehringer Ingelheim
• Can-Fite BioPharma
• Celgene
• Celldex Therapeutics
• Celltrion
• Cel-Sci
• ChemoCentryx
• Chugai Pharmaceutical
• Coherus BioSciences
• CTI BioPharma
• CureVac
• Cytos Biotachnology
• Daiichi Sankyo
• Eisai
• Eli Lilly
• Fortress Biotech
• Galena Biopharma
• Genexine
• Genmab
• Gilead Sciences
• GSK
• GlobeImmune
• Gradalis
• Heat Biologics
• Hospira
• Idera
• Immatics
• ImmunoCellular Therapeutics
• Immunomedics
• ImmuPharma
• Immutep
• Incyte
• Inovio Pharmaceuticals
• Intas Pharmaceuticals
• Invion
• ISA Pharmaceuticals
• Janssen Biotech
• Juvaris Biotherapeutics
• KaloBios Pharmaceuticals
• Kyowa Hakko Kirin
• Lexicon Pharmaceuticals
• MedImmune
• Morphotek
• Neovii Biotech
• Northwest Biotherapeutics
• Novartis
• NovaRx
• Novo Nordisk
• OncoMed Pharmaceuticals
• Oncothyreon
• Oncovir Inc.
• Opexa Therapeutics Inc.
• Oxford BioMedica
• Pfizer
• Prima BioMed
• Principia
• Progenics
• Provectus Biopharmaceuticals
• Regeneron
• Sandoz
• Sanofi
• Santarus
• Seattle Genetics
• Sotio
• Spectrum Pharmaceuticals
• Takeda
• TG Therapeutics
• Transgene
• UbiVac
• UCB
• Vaccinex
• Vaccinogen
• Vaxon Biotech
• Vertex Pharmaceuticals
• Vical
• Vitae Pharmaceuticals
• XBiotech

[Market driver]
• Growing prevalence of cancer and autoimmune diseases
• For a full, detailed list, view our report

[Market challenge]
• Patent expiries of top-selling drugs
• For a full, detailed list, view our report

[Market trend]
• Increase in awareness programs
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings
• Assumptions

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Overview: Immunotherapy
• Types of immunotherapy
• Key events
• Reimbursement policies
• Orphan drug designation and regulatory approvals

PART 06: Pipeline portfolio
• Anticipated number of immuno-oncology pipeline assets with single and multiple indications by 2020

PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 08: Market segmentation by type of immunotherapy
• mAbs
• Immune checkpoint inhibitors
• Vaccines
• Non-specific immunotherapies

PART 09: Market segmentation by therapy area

PART 10: Geographical segmentation
• Global immunotherapy drugs market by geographical segmentation 2015-2020
• Immunotherapy drugs market in Americas
• Immunotherapy drugs market in EMEA
• Immunotherapy drugs market in APAC

PART 11: Market drivers
• Growing prevalence of cancer and autoimmune diseases
• Rise in older population
• Increase in demand for mAbs
• Patient assistance programs
• Promising pipeline

PART 12: Impact of drivers

PART 13: Market challenges
• Patent expiries of top-selling drugs
• High costs of biologicals
• Poor diagnosis and screening
• Adverse effects
• Stringent regulations

PART 14: Impact of drivers and challenges

PART 15: Market trends
• Increase in awareness programs
• Emergence of targeted and combination therapies
• Emergence of biosimilars
• Strategic alliances
• Expected entry of novel vaccines

PART 16: Vendor landscape
• Competitive scenario
• Market share analysis 2015
• F. Hoffmann-La Roche
• AbbVie
• Johnson & Johnson
• Merck
• Amgen
• BMS
• Other prominent vendors

PART 17: Appendix
• List of abbreviations

PART 18: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Types of immunotherapy
Exhibit 03: Key events in discovery and approvals of immunotherapy drugs
Exhibit 04: Immunotherapy drugs approved by US FDA in 2015
Exhibit 05: US FDA orphan drug designations and approvals list for immunotherapy drugs
Exhibit 06: EU orphan drug designations and approvals list for immunotherapy drugs
Exhibit 07: Phase III pipeline molecules for mAbs
Exhibit 08: Phase II pipeline molecules for mAbs
Exhibit 09: Phase I pipeline molecules for mAbs
Exhibit 10: Pipeline molecules for immune checkpoint inhibitors
Exhibit 11: Phase III pipeline molecules for vaccines
Exhibit 12: Phase II pipeline molecules for vaccines
Exhibit 13: Phase I pipeline molecules for vaccines
Exhibit 14: Near-launch immuno-oncology pipeline assets
Exhibit 15: Global immunotherapy drugs market 2015-2020 ($ billions)
Exhibit 16: Factors influencing global immunotherapy drugs market
Exhibit 17: Challenges faced by US immunologists while prescribing immunotherapy drugs 2015
Exhibit 18: SWOT analysis of global immunotherapy drugs market
Exhibit 19: Five forces analysis
Exhibit 20: Market segmentation by type of immunotherapy drug
Exhibit 21: Timeline of mAbs approval for cancer by US FDA
Exhibit 22: Timeline of mAbs approval for autoimmune, respiratory, and ophthalmic diseases by US FDA
Exhibit 23: Global mAbs market 2015-2020 ($ billions)
Exhibit 24: Key drivers and challenges of global monoclonal antibodies drugs market
Exhibit 25: Top vendor offerings in global mAbs market
Exhibit 26: Global immune checkpoint inhibitors market 2015-2020 ($ billions)
Exhibit 27: Key driver and challenge for global immune checkpoint inhibitors market
Exhibit 28: Top vendor offerings in global immune checkpoint inhibitors market
Exhibit 29: Global vaccines market 2015-2020 ($ billions)
Exhibit 30: Segmentation of global vaccines market by application 2015
Exhibit 31: Key drivers and challenges of global vaccines market
Exhibit 32: Top vendor offerings in global vaccines market
Exhibit 33: Global non-specific immunotherapies market 2015-2020 ($ billions)
Exhibit 34: Key drivers and challenges of global non-specific immunotherapies market
Exhibit 35: Top vendor offerings in global non-specific immunotherapies market
Exhibit 36: Segmentation of global immunotherapy drugs market by type of immunotherapy 2015
Exhibit 37: Global immunotherapy drugs market; YoY revenue and growth rate based on type of immunotherapy 2015-2020 ($ billions)
Exhibit 38: Global immunotherapy drugs market segmentation by therapy area
Exhibit 39: Segmentation of global immunotherapy drugs market by therapy area 2015
Exhibit 40: Segmentation of global immunotherapy drugs market by geography 2015
Exhibit 41: Global immunotherapy drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 42: Immunotherapy drugs market in Americas 2015-2020 ($ billions)
Exhibit 43: Market share in the Americas by type of immunotherapy 2015
Exhibit 44: Immunotherapy drugs market in EMEA 2015-2020 ($ billions)
Exhibit 45: Market share in Europe by type of immunotherapy 2015
Exhibit 46: Immunotherapy drugs market in APAC 2015-2020 ($ billions)
Exhibit 47: Market share in APAC by type of immunotherapy 2015
Exhibit 48: Global immunotherapy drugs market: YoY revenue and growth based on geography 2015-2020 ($ billions)
Exhibit 49: Global incidence of cancers 2015 and 2020
Exhibit 50: Population aged 60 years and over: World, developed, and developing regions (millions)
Exhibit 51: Patient assistance programs for immunotherapy drugs
Exhibit 52: Some pipeline molecules for immunotherapy drugs
Exhibit 53: Impact of drivers
Exhibit 54: Approvals and patent expiries of top-selling immunotherapy drugs
Exhibit 55: Average annual treatment cost per patient for some immunotherapy drugs 2014 ($ millions)
Exhibit 56: Impact of drivers and challenges
Exhibit 57: Expected combination regimen launches in immune-oncology 2015-2020
Exhibit 58: Market share analysis of top vendors0
Exhibit 59: Competitive assessment of top 10 immunotherapy drugs 2015 ($ billions)1
Exhibit 60: YoY sales comparison of top five immunotherapy drugs 2013-2015 ($ billions)1
Exhibit 61: F. Hoffmann-La Roche: Immunotherapy drugs segmentation by revenue 20152
Exhibit 62: F. Hoffmann-La Roche: Top-selling immunotherapy drugs 20152
Exhibit 63: F. Hoffmann-La Roche: YoY revenue and growth rate of MabThera/Rituxan (oncology and immunology indications) 2013-2015 ($ billions)
Exhibit 64: F. Hoffmann-La Roche: YoY revenue and growth rate of MabThera/Rituxan (immunology indications only) 2013-2015 ($ billions)4
Exhibit 65: F. Hoffmann-La Roche: YoY revenue and growth rate of Actemra/RoActemra 2013-2015 ($ billions)5
Exhibit 66: F. Hoffmann-La Roche: Actemra/RoActemra geographic segmentation by revenue 20155
Exhibit 67: F. Hoffmann-La Roche: MabThera/Rituxan geographic segmentation by revenue 20156
Exhibit 68: F. Hoffmann-La Roche: YoY revenue and growth rate of Avastin 2012-2015 ($ billions)7
Exhibit 69: F. Hoffmann-La Roche: YoY revenue and growth rate of Herceptin 2012-2015 ($ billions)8
Exhibit 70: F. Hoffmann-La Roche: YoY revenue and growth rate of Herceptin in US 2013-2015 ($ billions)8
Exhibit 71: F. Hoffmann-La Roche: YoY revenue and growth rate of Herceptin in EU 2013-2015 ($ billions)8
Exhibit 72: F. Hoffmann-La Roche: YoY revenue and growth rate of Herceptin in Japan 2013-2015 ($ millions)9
Exhibit 73: F. Hoffmann-La Roche: YoY revenue and growth rate of Perjeta 2012-2015 ($ billions)0
Exhibit 74: F. Hoffmann-La Roche: YOY revenue and growth rate of Kadcyla 2013-2015 ($ billions)1
Exhibit 75: F. Hoffmann-La Roche: Key takeaways3
Exhibit 76: AbbVie: Immunotherapy drugs segmentation by revenue 20154
Exhibit 77: AbbVie: YoY revenue and growth rate of HUMIRA 2013-2015 ($ billions)5
Exhibit 78: AbbVie: YoY revenue and growth rate of HUMIRA in US 2013-2015 ($ billions)5
Exhibit 79: AbbVie: YoY revenue and growth rate of HUMIRA in ROW 2013-2015 ($ billions)5
Exhibit 80: AbbVie: Sales of HUMIRA in major markets 20156
Exhibit 81: AbbVie: Key takeaways7
Exhibit 82: Johnson & Johnson: Key immunotherapy drugs segmentation by revenue 20158
Exhibit 83: Johnson & Johnson: Top-selling immunotherapy drugs 20158
Exhibit 84: Johnson & Johnson: YoY revenue and growth rate of Remicade 2012-2015 ($ billions)9
Exhibit 85: Johnson & Johnson: YoY revenue and growth rate of Stelara 2012-2015 ($ billions)0
Exhibit 86: Johnson & Johnson: YoY revenue and growth rate of Stelara in US 2012-2015 ($ billions)0
Exhibit 87: Johnson & Johnson: YoY revenue and growth rate of Stelara in ROW 2012-2015 ($ millions)0
Exhibit 88: Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria 2012-2015 ($ billions)1
Exhibit 89: Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria in the US 2012-2015 ($ billions)1
Exhibit 90: Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria in ROW 2012-2015 ($ billions)2
Exhibit 91: Johnson & Johnson: Key takeaways3
Exhibit 92: Merck: Business segmentation by revenue 20154
Exhibit 93: Merck: Immunotherapy drugs segmentation by revenue 20155
Exhibit 94: Merck: Top-selling immunotherapy drugs 20156
Exhibit 95: Merck: YoY revenue and growth rate of Gardasil/Gardasil9 2012-2015 ($ billions)7
Exhibit 96: Merck: YoY revenue and growth rate of ProQuad/M-M-R II/Varivax 2012-2015 ($ billions)8
Exhibit 97: Merck: YoY revenue and growth rate of Zostavax 2012-2015 ($ millions)8
Exhibit 98: Merck: YoY revenue and growth rate of Pneumovax 23 2012-2015 ($ millions)9
Exhibit 99: Merck: YoY revenue and growth rate of RotaTeq 2012-2015 ($ millions)9
Exhibit 100: Merck: Key takeaways2
Exhibit 101: Amgen: Top-selling immunotherapy drugs 20153
Exhibit 102: Amgen: YoY revenue and growth rate of Enbrel in US and Canada 2012-2015 ($ billions)4
Exhibit 103: Amgen: YoY revenue and growth rate of Enbrel in US 2012-2015 ($ billions)4
Exhibit 104: Amgen: YoY revenue and growth rate of Enbrel in Canada 2012-2015 ($ millions)4
Exhibit 105: Amgen: YoY revenue and growth rate generated from net product sales of Xgeva 2012-2015 ($ billions)5
Exhibit 106: Amgen: YoY revenue and growth rate generated from net product sales of Prolia 2012-2015 ($ billions)5
Exhibit 107: Amgen: YoY revenue and growth rate of Vectibix in US 2012-2015 ($ millions)6
Exhibit 108: Amgen: YoY revenue and growth rate of Vectibix in ROW 2012-2015 ($ millions)6
Exhibit 109: Amgen: Key takeaways9
Exhibit 110: BMS: Business segmentation by revenue 20150
Exhibit 111: BMS: Immunotherapy drugs segmentation by revenue 20150
Exhibit 112: BMS: Top-selling immunotherapy drugs 20151
Exhibit 113: BMS: YoY revenue and growth rate of Orencia 2012-2015 ($ billions)2
Exhibit 114: BMS: YoY revenue and growth rate generated from net product sales of Yervoy 2012-2015 ($ billions)2
Exhibit 115: BMS: YoY revenue and growth rate of Erbitux in US, Canada, and Japan 2012-2015 ($ millions)3
Exhibit 116: BMS: Key takeaways



【掲載企業】

AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company (BMS), F. Hoffmann-La Roche AG, Johnson & Johnson Private Ltd., Merck & Co. Inc, AB Science, Ablynx, Acorda Therapeutics, ADC Therapeutics, Aduro Biotech, Advantagene, Advaxis, Agensys Inc., Agenus Inc., Alder Biopharmaceuticals, AlphaVax, Altor BioScience, Antares Pharma, Antigen Express, Argos Therapeutics Inc., Astellas Pharma, AstraZeneca, AVAX Technologies, Bavarian Nordic, Baxter, Bayer, Biogen, Biotech Pharmaceutical, Biothera, Boehringer Ingelheim, Can-Fite BioPharma, Celgene, Celldex Therapeutics, Celltrion, Cel-Sci, ChemoCentryx, Chugai Pharmaceutical, Coherus BioSciences, CTI BioPharma, CureVac, Cytos Biotachnology, Daiichi Sankyo, Eisai, Eli Lilly, Fortress Biotech, Galena Biopharma, Genexine, Genmab, Gilead Sciences, GSK, GlobeImmune, Gradalis, Heat Biologics, Hospira, Idera, Immatics, ImmunoCellular Therapeutics, Immunomedics, ImmuPharma, Immutep, Incyte, Inovio Pharmaceuticals, Intas Pharmaceuticals, Invion, ISA Pharmaceuticals, Janssen Biotech, Juvaris Biotherapeutics, KaloBios Pharmaceuticals, Kyowa Hakko Kirin, Lexicon Pharmaceuticals, MedImmune, Morphotek, Neovii Biotech, Northwest Biotherapeutics, Novartis, NovaRx, Novo Nordisk, OncoMed Pharmaceuticals, Oncothyreon, Oncovir Inc., Opexa Therapeutics Inc., Oxford BioMedica, Pfizer, Prima BioMed, Principia, Progenics, Provectus Biopharmaceuticals, Regeneron, Sandoz, Sanofi, Santarus, Seattle Genetics, Sotio, Spectrum Pharmaceuticals, Takeda, TG Therapeutics, Transgene, UbiVac, UCB, Vaccinex, Vaccinogen, Vaxon Biotech, Vertex Pharmaceuticals, Vical, Vitae Pharmaceuticals, XBiotech.

【資料のキーワード】

免疫治療薬、モノクローナル抗体、免疫チェックポイント阻害薬、ワクチン、非特異的免疫療法

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[免疫治療薬の世界市場:モノクローナル抗体、免疫チェックポイント阻害薬、ワクチン、非特異的免疫療法] (Global Immunotherapy Drugs 2016-2020 / IRTNTR8772)販売に関する免責事項
[免疫治療薬の世界市場:モノクローナル抗体、免疫チェックポイント阻害薬、ワクチン、非特異的免疫療法] (Global Immunotherapy Drugs 2016-2020 / IRTNTR8772)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆